Rossari Biotech Ltd will set up a wholly owned subsidiary in Singapore with an investment of USD 10 million. Expected by Q4 FY26, the entity will strengthen global expansion and operate in the chemical industry. The move highlights Rossari’s strategy to enhance international presence and long-term growth.
Rossari Biotech Ltd, a leading Indian specialty chemicals manufacturer, has announced plans to incorporate a wholly owned subsidiary in Singapore with an initial investment of up to USD 10 million, disbursed in tranches. The new entity, tentatively named Rossari (Singapore) Pte. Limited, will serve as a strategic hub for global investment and expansion.
Key Highlights
-
Board Approval: The company’s board has formally approved the incorporation of the Singapore-based subsidiary.
-
Investment Value: An initial USD 10 million will be infused, strengthening Rossari’s international footprint.
-
Timeline: Incorporation is expected to be completed by Q4 FY26, subject to regulatory approvals.
-
Strategic Purpose: The subsidiary will act as a gateway to global markets, enhancing Rossari’s presence in the chemical and allied industries.
-
Ownership: Rossari Biotech will hold 100% equity in the new entity, ensuring full control and alignment with its corporate vision.
Why It Matters
This move underscores Rossari Biotech’s ambition to scale internationally, diversify its portfolio, and tap into Singapore’s strategic position as a global business hub. It reflects the company’s commitment to long-term growth and innovation in specialty chemicals.
Sources: ScanX News, FilingReader, Rediff Money